Galectin Therapeutics Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
37
- Stock Symbol
-
GALT
- Investments
-
1
- Share Price
-
$2.51
- (As of Friday Closing)
Galectin Therapeutics General Information
Description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Contact Information
Website
www.galectintherapeutics.comCorporate Office
- 4960 Peachtree Industrial Boulevard
- Suite 240
- Norcross, GA 30071
- United States
Corporate Office
- 4960 Peachtree Industrial Boulevard
- Suite 240
- Norcross, GA 30071
- United States
Galectin Therapeutics Stock Performance
As of 11-Jul-2025, Galectin Therapeutics’s stock price is $2.51. Its current market cap is $155M with 63.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.51 | $2.45 | $0.73 - $3.90 | $155M | 63.3M | 594K | -$0.72 |
Galectin Therapeutics Financials Summary
As of 31-Mar-2025, Galectin Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 170,428 | 160,712 | 145,757 | 83,403 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (39,211) | (41,808) | (38,471) | (37,763) |
| Net Income | (45,189) | (47,047) | (41,066) | (38,776) |
| Total Assets | 9,528 | 17,495 | 28,200 | 21,285 |
| Total Debt | 107,987 | 106,245 | 71,787 | 39,868 |
Galectin Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Galectin Therapeutics Comparisons
Industry
Financing
Details
Galectin Therapeutics Competitors (38)
One of Galectin Therapeutics’s 38 competitors is Sagimet Biosciences, a Formerly VC-backed company based in San Mateo, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sagimet Biosciences | Formerly VC-backed | San Mateo, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| Light Chain Bioscience | Formerly PE-Backed | Geneva, Switzerland | ||||
| GeoVax Labs | Corporation | Smyrna, GA |
Galectin Therapeutics Patents
Galectin Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20140235571-A1 | Method for treatment of pulmonary fibrosis | Active | 20-Feb-2013 | ||
| US-20160213703-A1 | Method for treatment of pulmonary fibrosis | Active | 20-Feb-2013 | ||
| US-9339515-B2 | Method for treatment of pulmonary fibrosis | Active | 20-Feb-2013 | ||
| US-9968631-B2 | Method for treatment of pulmonary fibrosis | Active | 20-Feb-2013 | ||
| ES-2698101-T3 | Compounds of carbohydrate with galactose residues for the treatment of diabetic nephropathy and associated disorders | Active | 10-Oct-2012 | C08B37/006 |
Galectin Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Galectin Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Galectin Therapeutics Acquisitions (1)
Galectin Therapeutics’s most recent deal was a Merger/Acquisition with Pro-Pharmaceuticals. The deal was made on 15-May-2001.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pro-Pharmaceuticals | 15-May-2001 | Merger/Acquisition | Drug Discovery |
Galectin Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 30, 2021
34.57 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,042
Rank
Percentile
Pharmaceuticals
Industry
of 947
Rank
Percentile
Biotechnology
Subindustry
of 427
Rank
Percentile
Galectin Therapeutics FAQs
-
When was Galectin Therapeutics founded?
Galectin Therapeutics was founded in 2000.
-
Where is Galectin Therapeutics headquartered?
Galectin Therapeutics is headquartered in Norcross, GA.
-
What is the size of Galectin Therapeutics?
Galectin Therapeutics has 37 total employees.
-
What industry is Galectin Therapeutics in?
Galectin Therapeutics’s primary industry is Biotechnology.
-
Is Galectin Therapeutics a private or public company?
Galectin Therapeutics is a Public company.
-
What is Galectin Therapeutics’s stock symbol?
The ticker symbol for Galectin Therapeutics is GALT.
-
What is the current stock price of Galectin Therapeutics?
As of 11-Jul-2025 the stock price of Galectin Therapeutics is $2.51.
-
What is the current market cap of Galectin Therapeutics?
The current market capitalization of Galectin Therapeutics is $155M.
-
Who are Galectin Therapeutics’s competitors?
Sagimet Biosciences, Inovio Pharmaceuticals, Rein Therapeutics, Light Chain Bioscience, and GeoVax Labs are some of the 38 competitors of Galectin Therapeutics.
-
What is Galectin Therapeutics’s annual earnings per share (EPS)?
Galectin Therapeutics’s EPS for 12 months was -$0.72.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
